ACS
Reference
Comments/Instructions
The platelet inhibitor ticagrelor is superior to clopidogrel among patients with acute coronary syndromes who are scheduled to undergo invasive management, according to a prespecified subanalysis of the industry-funded, phase III PLATO study. The findings appear online in the Lancet.
Nearly 13,500 patients with acute coronary syndromes, with or without ST-segment elevation and for whom early invasive treatment was planned, were randomized to receive ticagrelor or clopidogrel for 6 to 12 months. By 1 year, the primary endpoint — a composite of cardiovascular death, MI, or stroke — had occurred significantly less often with ticagrelor than with clopidogrel (9% vs. 11%). Total major bleeding did not differ significantly between the groups.
A commentator concludes: "These compelling results support ticagrelor as a new standard of care in acute coronary syndromes."
Tags
- Cardiovascular
No comments so far